Avanos Medical
AVNS
257 hedge funds and large institutions have $631M invested in Avanos Medical in 2026 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 71 increasing their positions, 72 reducing their positions, and 42 closing their positions.
24% more capital invested
Capital invested by funds: $510M → $631M (+$121M)
1% less repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 72
1.1% less ownership
Funds ownership: 97.78% → 96.68% (-1.1%)
6% less funds holding
Funds holding: 274 → 257 (-17)
29% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 42
Top Buyers
Top Sellers
| 1 |
AC
Armistice Capital
New York
|
-$16.2M |
| 2 |
Millennium Management
New York
|
-$9.67M |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$7.72M |
| 4 |
D.E. Shaw & Co
New York
|
-$7.26M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$3.8M |
AVNS Hedge Fund Activity: Q1 2026 in Review
257 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Avanos Medical (AVNS) for Q1 2026, worth a combined $631M — up 24% from $510M a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of AVNS and 30 opened new positions — a net loss of 12 holders — while 72 trimmed existing stakes and 71 added.
The largest buyer was Boone Capital Management, opening a new position worth an estimated $16M. The largest seller was Armistice Capital, cutting an estimated $16.2M.
- 257 institutional investors held Avanos Medical (AVNS) as of Q1 2026, down from 274 in Q4 2025.
- Funds reported $631M of Avanos Medical stock for Q1 2026, up 24% quarter-over-quarter.
- 30 funds opened new Avanos Medical positions in Q1 2026 and 42 closed out, a net change of -12 holders.
- The largest Avanos Medical buyer in Q1 2026 was Boone Capital Management, an estimated $16M added.
- The largest Avanos Medical seller in Q1 2026 was Armistice Capital, an estimated $16.2M sold.
Based on aggregated 13F filings for Q1 2026.